Krystal stock: buy or sell?
December 6th, 2019
Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases.
Should I buy Krystal stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, 2 buy setups are elegible for Krystal Biotech stock now:
|New all-time high||Yes|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Krystal stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we collected 11 ratings published for KRYS stock in the last 30 days. The general sentiment of these ratings is bullish for KRYS stock, with 10 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-9-24||Goldman Sachs Group||n/a||Neutral|
Krystal stock analysis
After reaching all time highs on Dec 4th, Krystal skyrocketed 4.54% today to $62.64.
After topping to all time highs on December/4, Krystal skyrocketed 4.54% to $62.64. Since price and SMA200d lines crossed up on October, KRYS climbed $29.47 (88.85%). From a daily perspective, KRYS is in a short term uptrend after plotting its last bottom ($38.77, on Oct 31st) higher than the previous bottom, and its last top ($65.90, on December/4) also over the previous top. Now trading in between its last bottom and last top KRYS might consolidate in a plain range, waiting to break out over $65.90 or down under $38.77. On Dec/4, KRYS hit a new all time high, pushing higher than on Monday tops. Check different trading setups that use ATHs as triggers.
Krystal ended this week at $62.64 after topping to a new all time high ($65.90) and boosted an extraordinary 10.85%. With this, it's been 5 climbing weeks in a row, soaring a 53.22%.
This week, SMA10w and SMA20w crossed up triggering a rise of 10.85%. Since price and SMA20w lines crossed up by mid November, KRYS climbed $20.08 (47.18%).
Krystal stock price history
Krystal stock went public on September 20th, 2017 with a price of $10.501. Since then, KRYS stock grew a 496.60%, with an average of 248.30% per year. If you had invested $1,000 in Krystal stock in 2017, it would worth $4,966.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Krystal stock historical price chart
KRYS stock reached all-time highs on Dec/4 with a price of $65.90.
Krystal stock price target is $58.80How much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' KRYS stock price predictions in the hope that they will be met as they may be wrong and not met. We detected 9 price targets for Krystal stock released in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-9-24||Goldman Sachs Group||Initiates||n/a||$60.00||-|
|2019-8-6||HC Wainwright||Raises Target||$56.00||$59.00||5.4%|
|2019-6-24||HC Wainwright||Raises Target||$38.00||$56.00||47.4%|
|2019-6-24||Chardan Capital||Raises Target||$57.50||$75.00||30.4%|
|2019-3-12||Chardan Capital||Raises Target||$50.00||$57.50||15%|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn March, Krystal presented its financial report, posting an excellent gain for the Earnings per Share (EPS). Analyst were expecting $-0.24 per share, but Krystal Biotech posted $-0.28.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn , Krystal annual revenues to million USD from marked in . When comparing vs , , profit margin (that is, the net income divided by revenues) a to .
Quarterly financial resultsReported quarter earnings marked $-3.71 million with a profit margin of . Profit margin stayed constant a 0.00% compared to previous quarter when profit margin was inf%. When comparing turnover to same quarter last year, Krystal sales marked a neutral move and remained constant a nan%. Looking back to recent quarterly results, Krystal Biotech posted 7 positive quarters in a row.
Krystal ownershipWhen you are planning to invest in a stock, it's worth to have a look its ownership structure.
Krystal Biotech shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 32.99% of all shares.
In case of Krystal Biotech stock, 43.14% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for KRYS stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Krystal:
|Market cap||$1.1 B|
|Total shares||17.3 M|
|Float shares||10.0 M|
|- Institutional holdings (%)||43.1%|
|- Insider holdings (%)||33.0%|
|Shares in short selling||0.0%|
|Friday, December 6th, 2019|
|Day range||$59.08 - $62.86|
|Average true range||$4.41|
|50d mov avg||$44.74|
|100d mov avg||$44.84|
|200d mov avg||$38.39|
Krystal performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. For Krystal, the benchmark is made against .